DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups

British Journal of Haematology

Volumn 159, Issue 2, 2012, Pages 182-190

  Ohgami, Robert S ^a   Ma, Lisa ^a   Ren, Li ^a   Weinberg, Olga K ^b   Seetharam, Mahesh ^c   Gotlib, Jason R ^a   Arber, Daniel A ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

^c Roger Williams Medical Center ^*  (United States)

Author keywords

Acute myeloid leukaemia; ALOX12; GSTM1; Methylation analysis; Multilineage dysplasia; Myelodysplastic syndrome

Indexed keywords

FRIZZLED PROTEIN; GLUTATHIONE TRANSFERASE M1; SULFOTRANSFERASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; AGED; ALOX12 GENE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; FEMALE; FZD9 GENE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GSTM1 GENE; HS3ST2 GENE; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRIORITY JOURNAL;

ABNORMAL KARYOTYPE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARACHIDONATE 12-LIPOXYGENASE; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; FRIZZLED RECEPTORS; GLUTATHIONE TRANSFERASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84866869795     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12029     Document Type: Article

References (49)

1. Agrawal, S., Hofmann, W.K., Tidow, N., Ehrich, M., van den Boom, D., Koschmieder, S., Berdel, W.E., Serve, H. & Muller-Tidow, C. (2007) The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood, 109, 3895-3905.
2. Ahn, J.Y., Seo, K., Weinberg, O., Boyd, S.D. & Arber, D.A. (2009) A comparison of two methods for screening CEBPA mutations in patients with acute myeloid leukemia. The Journal of Molecular Diagnostics, 11, 319-323.
3. Alvarez, S., Suela, J., Valencia, A., Fernandez, A., Wunderlich, M., Agirre, X., Prosper, F., Martin-Subero, J.I., Maiques, A., Acquadro, F., Rodriguez Perales, S., Calasanz, M.J., Roman-Gomez, J., Siebert, R., Mulloy, J.C., Cervera, J., Sanz, M.A., Esteller, M. & Cigudosa, J.C. (2010) DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS ONE, 5, e12197.
4. Arber, D.A., Snyder, D.S., Fine, M., Dagis, A., Niland, J. & Slovak, M.L. (2001) Myeloperoxidase immunoreactivity in adult acute lymphoblastic leukemia. American Journal of Clinical Pathology, 116, 25-33.
5. Arber, D.A., Carter, N.H., Ikle, D. & Slovak, M.L. (2003a) Value of combined morphologic, cytochemical, and immunophenotypic features in predicting recurrent cytogenetic abnormalities in acute myeloid leukemia. Human Pathology, 34, 479-483.
6. Arber, D.A., Stein, A.S., Carter, N.H., Ikle, D., Forman, S.J. & Slovak, M.L. (2003b) Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. American Journal of Clinical Pathology, 119, 672-680.
7. Byrd, J.C., Mrozek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Patil, S.R., Rao, K.W., Watson, M.S., Koduru, P.R., Moore, J.O., Stone, R.M., Mayer, R.J., Feldman, E.J., Davey, F.R., Schiffer, C.A., Larson, R.A. & Bloomfield, C.D. (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia group B (CALGB 8461). Blood, 100, 4325-4336.
8. Das, P., Shaik, A.P. & Bammidi, V.K. (2009) Meta-analysis study of glutathione-S-transferases (GSTM1, GSTP1, and GSTT1) gene polymorphisms and risk of acute myeloid leukemia. Leukaemia & Lymphoma, 50, 1345-1351.
9. Deneberg, S., Grovdal, M., Karimi, M., Jansson, M., Nahi, H., Corbacioglu, A., Gaidzik, V., Dohner, K., Paul, C., Ekstrom, T.J., Hellstrom-Lindberg, E. & Lehmann, S. (2010) Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia, 24, 932-941.
10. Diaz-Beya, M., Rozman, M., Pratcorona, M., Torrebadell, M., Camos, M., Aguilar, J.L. & Esteve, J. (2010) The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status. Blood, 116, 6147-6148.
11. Dohner, K., Schlenk, R.F., Habdank, M., Scholl, C., Rucker, F.G., Corbacioglu, A., Bullinger, L., Frohling, S. & Dohner, H. (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 106, 3740-3746.
12. Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., Bigerna, B., Pacini, R., Pucciarini, A., Liso, A., Vignetti, M., Fazi, P., Meani, N., Pettirossi, V., Saglio, G., Mandelli, F., Lo-Coco, F., Pelicci, P.G. & Martelli, M.F. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New England Journal of Medicine, 352, 254-266.
13. Figueroa, M.E., Skrabanek, L., Li, Y., Jiemjit, A., Fandy, T.E., Paietta, E., Fernandez, H., Tallman, M.S., Greally, J.M., Carraway, H., Licht, J.D., Gore, S.D. & Melnick, A. (2009) MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood, 114, 3448-3458.
14. Figueroa, M.E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P.J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., Campagne, F., Mazumdar, M., Greally, J.M., Valk, P.J., Lowenberg, B., Delwel, R. & Melnick, A. (2010) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell, 17, 13-27.
15. Frohling, S., Schlenk, R.F., Stolze, I., Bihlmayr, J., Benner, A., Kreitmeier, S., Tobis, K., Dohner, H. & Dohner, K. (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. Journal of Clinical Oncology, 22, 624-633.
16. Funk, C.D., Chen, X.S., Johnson, E.N. & Zhao, L. (2002) Lipoxygenase genes and their targeted disruption. Prostaglandins & Other Lipid Mediators, 68-69, 303-312.
17. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 92, 2322-2333.
18. Heerema-McKenney, A. & Arber, D.A. (2009) Acute myeloid leukemia. Hematology/oncology Clinics of North America, 23, 633-654.
19. Jiang, Y., Dunbar, A., Gondek, L.P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y. & Maciejewski, J.P. (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood, 113, 1315-1325.
20. Johns, L.E. & Houlston, R.S. (2000) Glutathione S-transferase mu1 (GSTM1) status and bladder cancer risk: a meta-analysis. Mutagenesis, 15, 399-404.
21. Karasawa, T., Yokokura, H., Kitajewski, J. & Lombroso, P.J. (2002) Frizzled-9 is activated by Wnt-2 and functions in Wnt/beta-catenin signaling. Journal of Biological Chemistry, 277, 37479-37486.
22. Khedhaier, A., Remadi, S., Corbex, M., Ahmed, S.B., Bouaouina, N., Mestiri, S., Azaiez, R., Helal, A.N. & Chouchane, L. (2003) Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma. British Journal of Cancer, 89, 1502-1507.
23. Kroeger, H., Jelinek, J., Estecio, M.R., He, R., Kondo, K., Chung, W., Zhang, L., Shen, L., Kantarjian, H.M., Bueso-Ramos, C.E. & Issa, J.P. (2008) Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood, 112, 1366-1373.
24. Levis, M., Allebach, J., Tse, K.F., Zheng, R., Baldwin, B.R., Smith, B.D., Jones-Bolin, S., Ruggeri, B., Dionne, C. & Small, D. (2002) A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood, 99, 3885-3891.
25. Lugthart, S., Figueroa, M.E., Bindels, E., Skrabanek, L., Valk, P.J., Li, Y., Meyer, S., Erpelinck-Verschueren, C., Greally, J., Lowenberg, B., Melnick, A. & Delwel, R. (2011) Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood, 117, 234-241.
26. Martinez, R., Martin-Subero, J.I., Rohde, V., Kirsch, M., Alaminos, M., Fernandez, A.F., Ropero, S., Schackert, G. & Esteller, M. (2009) A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics, 4, 255-264.
27. Martin-Subero, J.I., Ammerpohl, O., Bibikova, M., Wickham-Garcia, E., Agirre, X., Alvarez, S., Bruggemann, M., Bug, S., Calasanz, M.J., Deckert, M., Dreyling, M., Du, M.Q., Durig, J., Dyer, M.J., Fan, J.B., Gesk, S., Hansmann, M.L., Harder, L., Hartmann, S., Klapper, W., Kuppers, R., Montesinos-Rongen, M., Nagel, I., Pott, C., Richter, J., Roman-Gomez, J., Seifert, M., Stein, H., Suela, J., Trumper, L., Vater, I., Prosper, F., Haferlach, C., Cruz Cigudosa, J. & Siebert, R. (2009) A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS ONE, 4, e6986.
28. Miesner, M., Haferlach, C., Bacher, U., Weiss, T., Macijewski, K., Kohlmann, A., Klein, H.U., Dugas, M., Kern, W., Schnittger, S. & Haferlach, T. (2010) Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). Blood, 116, 2742-2751.
29. Miyamoto, K., Asada, K., Fukutomi, T., Okochi, E., Yagi, Y., Hasegawa, T., Asahara, T., Sugimura, T. & Ushijima, T. (2003) Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene, 22, 274-280.
30. Nigam, S., Kumar, G.S., Sutherland, M., Schewe, T., Ikawa, H., Yamasaki, Y., Ueda, N. & Yamamoto, S. (1999) Metabolic suppression of platelet-type 12-lipoxygenase in human uterine cervix with invasive carcinoma. International Journal of Cancer, 82, 827-831.
31. Pulte, D., Gondos, A. & Brenner, H. (2010) Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010. Annals of Oncology, 21, 335-341.
32. Schnittger, S., Schoch, C., Kern, W., Mecucci, C., Tschulik, C., Martelli, M.F., Haferlach, T., Hiddemann, W. & Falini, B. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, 3733-3739.
33. Sheikhha, M.H., Awan, A., Tobal, K. & Liu Yin, J.A. (2003) Prognostic significance of FLT3 ITD and D835 mutations in AML patients. The Hematology Journal, 4, 41-46.
34. Slovak, M.L., Kopecky, K.J., Cassileth, P.A., Harrington, D.H., Theil, K.S., Mohamed, A., Paietta, E., Willman, C.L., Head, D.R., Rowe, J.M., Forman, S.J. & Appelbaum, F.R. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood, 96, 4075-4083.
35. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Theile, J. & Vardiman, J.W. (2008) WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC, Lyon.
36. Tallman, M.S., Andersen, J.W., Schiffer, C.A., Appelbaum, F.R., Feusner, J.H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C.D., Rowe, J.M. & Wiernik, P.H. (1997) All-trans-retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine, 337, 1021-1028.
37. Tsutsumi, C., Ueda, M., Miyazaki, Y., Yamashita, Y., Choi, Y.L., Ota, J., Kaneda, R., Koinuma, K., Fujiwara, S., Kisanuki, H., Ishikawa, M., Ozawa, K., Tomonaga, M. & Mano, H. (2004) DNA microarray analysis of dysplastic morphology associated with acute myeloid leukemia. Experimental Hematology, 32, 828-835.
38. Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., Zwahlen, M., Kampf, C., Wester, K., Hober, S., Wernerus, H., Bjorling, L. & Ponten, F. (2010) Towards a knowledge-based human protein atlas. Nature Biotechnology, 28, 1248-1250.
39. Voso, M.T., D'Alo, F., Putzulu, R., Mele, L., Scardocci, A., Chiusolo, P., Latagliata, R., Lo-Coco, F., Rutella, S., Pagano, L., Hohaus, S. & Leone, G. (2002) Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood, 100, 2703-2707.
40. Wakui, M., Kuriyama, K., Miyazaki, Y., Hata, T., Taniwaki, M., Ohtake, S., Sakamaki, H., Miyawaki, S., Naoe, T., Ohno, R. & Tomonaga, M. (2008) Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol. International Journal of Hematology, 87, 144-151.
41. Wandt, H., Schakel, U., Kroschinsky, F., Prange-Krex, G., Mohr, B., Thiede, C., Pascheberg, U., Soucek, S., Schaich, M. & Ehninger, G. (2008) MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood, 111, 1855-1861.
42. Wang, B., Huang, G., Wang, D., Li, A., Xu, Z., Dong, R., Zhang, D. & Zhou, W. (2010) Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. Journal of Hepatology, 53, 508-518.
43. Weinberg, O.K., Seetharam, M., Ren, L., Seo, K., Ma, L., Merker, J.D., Gotlib, J., Zehnder, J.L. & Arber, D.A. (2009a) Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood, 113, 1906-1908.
44. Weinberg, O.K., Ma, L., Seo, K., Beck, A.H., Pai, R.K., Morales, A., Kim, Y., Sundram, U., Tan, D., Horning, S.J., Hoppe, R.T., Natkunam, Y. & Arber, D.A. (2009b) Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin. American Journal of Surgical Pathology, 33, 591-598.
45. Whitman, S.P., Ruppert, A.S., Radmacher, M.D., Mrozek, K., Paschka, P., Langer, C., Baldus, C.D., Wen, J., Racke, F., Powell, B.L., Kolitz, J.E., Larson, R.A., Caligiuri, M.A., Marcucci, G. & Bloomfield, C.D. (2008) FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood, 111, 1552-1559.
46. Winn, R.A., Van Scoyk, M., Hammond, M., Rodriguez, K., Crossno, Jr, J.T., Heasley, L.E. & Nemenoff, R.A. (2006) Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. Journal of Biological Chemistry, 281, 26943-26950.
47. Wu, Q.L., Zierold, C. & Ranheim, E.A. (2009) Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia. Blood, 113, 3031-3039.
48. Yanada, M., Suzuki, M., Kawashima, K., Kiyoi, H., Kinoshita, T., Emi, N., Saito, H. & Naoe, T. (2005) Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience. European Journal of Haematology, 74, 418-423.
49. Yu, K.D., Di, G.H., Fan, L., Wu, J., Hu, Z., Shen, Z.Z., Huang, W. & Shao, Z.M. (2009) A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer. FASEB Journal, 23, 2274-2287.